<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822103</url>
  </required_header>
  <id_info>
    <org_study_id>RICE-retro</org_study_id>
    <nct_id>NCT04822103</nct_id>
  </id_info>
  <brief_title>A Real-World Study of Immune Checkpoint Inhibitors and Chemotherapy for Advanced Esophageal Cancer</brief_title>
  <official_title>A Real-World Study Evaluating the Efficacy and Safety of Immune Checkpoint Inhibitors and Chemotherapy for Advanced Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shantou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of neoadjuvant chemotherapy as standard therapy is well-established for locally&#xD;
      advanced esophageal cancer. Immunotherapeutic agents such as Immune checkpoint inhibitors has&#xD;
      been shown to improve objective response rate in solid tumors. However, there is a paucity of&#xD;
      data regarding the efficacy and safety of neoadjuvant immunotherapy plus chemotherapy in&#xD;
      esophageal cancer patients in real-world practice. This study set out to investigate whether&#xD;
      the combination of neoadjuvant chemotherapy and immune checkpoint inhibitors is beneficial to&#xD;
      improve the objective response rate as well as the pathological complete response rate in a&#xD;
      real-world scenario.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response rate (pCR)</measure>
    <time_frame>Three to five working days after surgery</time_frame>
    <description>The rate of pathologic complete response rate after the combined treatment of chemotherapy and immunotherapy following surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Three to five working days after surgery</time_frame>
    <description>The R0 resection rate of esophagectomy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Esophageal Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed as potentially resectable esophageal squamous cell carcinoma via&#xD;
        pathological specimen, KPS ≥ 80, has adequate organ function and no distant metastasis are&#xD;
        included in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically diagnosed as esophageal squamous cell carcinoma&#xD;
&#xD;
          -  KPS≥80&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  No distant metastasis&#xD;
&#xD;
          -  The diseases could be resected or potentially resectable assessed by a thoracic&#xD;
             oncologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  incomplete medical record which affects statistical analysis&#xD;
&#xD;
          -  have participated in previous interventional clinical trials&#xD;
&#xD;
          -  other situations evaluated by investigators not meet the enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guibin Qiao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guibin Qiao, MD</last_name>
    <phone>13602749153</phone>
    <email>guibinqiao@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guibin Qiao, MD</last_name>
      <phone>13602749153</phone>
      <email>guibinqiao@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Shujie Huang, MD</last_name>
      <phone>13592844883</phone>
      <email>shujie_huang@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shantou Central Hospital</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <zip>515031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junhui Fu, MD</last_name>
      <phone>13556301818</phone>
      <email>18029500042@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>March 28, 2021</last_update_submitted>
  <last_update_submitted_qc>March 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophageal cancer</keyword>
  <keyword>real-world study</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

